Colorectal Neoplasms

• 

  Subject Areas on Research

  • 3D image guidance assisted identification of colorectal cancer liver metastases not seen on intraoperative ultrasound: results from a prospective trial. 
  • 5-HTTLPR and use of antidepressants after colorectal cancer including a meta-analysis of 5-HTTLPR and depression after cancer. 
  • A Blueprint to Advance Colorectal Cancer Immunotherapies. 
  • A Comparative Effectiveness Trial of Alternate Formats for Presenting Benefits and Harms Information for Low-Value Screening Services: A Randomized Clinical Trial. 
  • A Cross-Cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, Prostate, Breast, and Colorectal Cancer. 
  • A Decision Aid to Promote Appropriate Colorectal Cancer Screening among Older Adults: A Randomized Controlled Trial. 
  • A General Cutoff Level Combined With Personalized Dynamic Change of Serum Carcinoembryonic Antigen Can Suggest Timely Use of FDG PET for Early Detection of Recurrent Colorectal Cancer. 
  • A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution. 
  • A Longitudinal Study of Adenoma Detection Rate in Gastroenterology Fellowship Training. 
  • A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma. 
  • A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer. 
  • A Validated Prognostic Multigene Expression Assay for Overall Survival in Resected Colorectal Cancer Liver Metastases. 
  • A formalin-fixed paraffin-embedded (FFPE)-based prognostic signature to predict metastasis in clinically low risk stage I/II microsatellite stable colorectal cancer. 
  • A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA) 
  • A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization. 
  • A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver. 
  • A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study. 
  • A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. 
  • A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer. 
  • A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. 
  • A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. 
  • A phase II study of trimetrexate therapy for metastatic colorectal carcinoma. 
  • A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. 
  • A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer. 
  • A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial). 
  • A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. A potential adjuvant program after resection of colorectal hepatic metastases. 
  • A prediction model for advanced colorectal neoplasia in an asymptomatic screening population. 
  • A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer. 
  • A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. 
  • A randomized pilot trial of a telephone-based couples intervention for physical intimacy and sexual concerns in colorectal cancer. 
  • A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. 
  • A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. 
  • A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard). 
  • A retrospective comparison of microwave ablation vs. radiofrequency ablation for colorectal cancer hepatic metastases. 
  • A simplified synthesis of the hypoxia imaging agent 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[(18)F]pentafluoropropyl)-acetamide ([18F]EF5). 
  • A statistic for comparing two correlated markers which are prognostic for time to an event. 
  • A systematic review of psychosocial interventions for colorectal cancer patients. 
  • A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US. 
  • ACR Appropriateness Criteria® Colorectal Cancer Screening. 
  • APC promoter hypermethylation contributes to the loss of APC expression in colorectal cancers with allelic loss on 5q. 
  • ASO Author Reflections: Implementation of a New Hepatic Artery Infusion Program for Colorectal Liver Metastases is Safe, Feasible, and Effective. 
  • Aberrant expression of maspin in idiopathic inflammatory bowel disease is associated with disease activity and neoplastic transformation. 
  • Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study. 
  • Accuracy of self-reports of fecal occult blood tests and test results among individuals in the carpentry trade. 
  • Activating mutation in MET oncogene in familial colorectal cancer. 
  • Activation of the mTOR Pathway by Oxaliplatin in the Treatment of Colorectal Cancer Liver Metastasis. 
  • Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure? 
  • Adapting a couple-based intimacy enhancement intervention to breast cancer: A developmental study. 
  • Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. 
  • Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. 
  • Addressing guideline and policy changes during pragmatic clinical trials. 
  • Adenoma recurrences after resection of colorectal carcinoma: results from the Southwest Oncology Group 9041 calcium chemoprevention pilot study. 
  • Adenoma-like adenocarcinoma: a subtype of colorectal carcinoma with good prognosis, deceptive appearance on biopsy and frequent KRAS mutation. 
  • Adjuvant chemotherapy for colorectal hepatic metastases: role of route of administration and timing. 
  • Adjuvant hepatic arterial chemotherapy following metastasectomy in patients with isolated liver metastases. 
  • Adjuvant therapy for colorectal cancer. 
  • Adult intussusception secondary to colorectal cancer in a young man: a case report. 
  • Advanced imaging and hospice use in end-of-life cancer care. 
  • After surgery for stage II or III colorectal cancer, more vs less frequent follow-up did not differ for 5-year mortality. 
  • Age-related vulnerabilities of older adults with colon adenomas: evidence from Project Prevent. 
  • Agrin in the Muscularis Mucosa Serves as a Biomarker Distinguishing Hyperplastic Polyps from Sessile Serrated Lesions. 
  • Aldolase B-Mediated Fructose Metabolism Drives Metabolic Reprogramming of Colon Cancer Liver Metastasis. 
  • Alternate statistical tools and limitations in genetic marker association studies in single-arm drug cancer trials. 
  • Alternative activation of extracellular signal-regulated protein kinases in curcumin and arsenite-induced HSP70 gene expression in human colorectal carcinoma cells. 
  • American Cancer Society Colorectal Cancer Survivorship Care Guidelines. 
  • An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. 
  • An electronic family health history tool to identify and manage patients at increased risk for colorectal cancer: protocol for a randomized controlled trial. 
  • An examination of racial differences in process and outcome of colorectal cancer care quality among users of the veterans affairs health care system. 
  • Analysis of colorectal cancer screening regimens. 
  • Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. 
  • Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions. 
  • Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. 
  • Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models. 
  • Antibody Responses to Streptococcus Gallolyticus Subspecies Gallolyticus Proteins in a Large Prospective Colorectal Cancer Cohort Consortium. 
  • Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. 
  • Antioxidant and DNA methylation-related nutrients and risk of distal colorectal cancer. 
  • Artificial neural networks improve the accuracy of cancer survival prediction. 
  • Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. 
  • Assessment of quality of cancer-related follow-up care from the cancer survivor's perspective. 
  • Association between Adult Height and Risk of Colorectal, Lung, and Prostate Cancer: Results from Meta-analyses of Prospective Studies and Mendelian Randomization Analyses. 
  • Association between p21 Ser31Arg polymorphism and cancer risk: a meta-analysis. 
  • Association between p53 Arg72Pro polymorphism and colorectal cancer risk: a meta-analysis. 
  • Association between tea consumption and risk of cancer: a prospective cohort study of 0.5 million Chinese adults. 
  • Association between two functional polymorphisms of insulin-like growth factor binding protein 3 and colorectal cancer risk in a Chinese population. 
  • Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial. 
  • Association of Financial Strain With Symptom Burden and Quality of Life for Patients With Lung or Colorectal Cancer. 
  • Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. 
  • Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer. 
  • Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. 
  • Associations between lifestyle factors and quality of life among older long-term breast, prostate, and colorectal cancer survivors. 
  • Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. 
  • Associations of red meat, fat, and protein intake with distal colorectal cancer risk. 
  • Availability of Healthcare Resources and Colorectal Cancer Outcomes Among Non-Hispanic White and Non-Hispanic Black Adults. 
  • Barriers to full colon evaluation for a positive fecal occult blood test. 
  • Baseline Colonoscopy Findings Associated With 10-Year Outcomes in a Screening Cohort Undergoing Colonoscopy Surveillance. 
  • Bcl-xL is an oncogenic driver in colorectal cancer. 
  • Bcl10 is not a target for frequent mutation in human carcinomas. 
  • Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. 
  • Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. 
  • Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk. 
  • Bevacizumab in colorectal cancer. 
  • Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. 
  • Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. 
  • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. 
  • Bevacizumab-associated fistula formation in postoperative colorectal cancer patients. 
  • Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. 
  • Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors. 
  • Biochemical modulation of 5-fluorouacil through dihydropyrimidine dehydrogenase inhibition: a Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancer. 
  • Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer. 
  • Biomarker signatures correlate with clinical outcome in refractory metastatic colorectal cancer patients receiving bevacizumab and everolimus. 
  • Black tea consumption and risk of rectal cancer in Moscow population. 
  • Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). 
  • Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. 
  • CD90(+) stromal cells are the major source of IL-6, which supports cancer stem-like cells and inflammation in colorectal cancer. 
  • CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. 
  • CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. 
  • CT during arterial portography: diagnostic pitfalls. 
  • CXCR4 expression predicts patient outcome and recurrence patterns after hepatic resection for colorectal liver metastases. 
  • Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer. 
  • Can screening older patients for cancer save lives? 
  • Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma. 
  • Cancer care quality measures: diagnosis and treatment of colorectal cancer. 
  • Cancer disparities in people with HIV: A systematic review of screening for non-AIDS-defining malignancies. 
  • Cancer in pregnancy: a review of the literature. Part I. 
  • Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX. 
  • Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. 
  • Carbohydrate recognition on MUC1-expressing targets enhances cytotoxicity of a T cell subpopulation. 
  • Caspase 3 in dying tumor cells mediates post-irradiation angiogenesis. 
  • Cells with pathogenic biallelic mutations in the human MUTYH gene are defective in DNA damage binding and repair. 
  • Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study. 
  • Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer. 
  • Characterization of sporadic colon cancer by patterns of genomic instability. 
  • Chemokine 25-induced signaling suppresses colon cancer invasion and metastasis. 
  • Chemotherapy use and patient treatment preferences in advanced colorectal cancer: a prospective cohort study. 
  • Chemotherapy-induced splenic volume increase is independently associated with major complications after hepatic resection for metastatic colorectal cancer. 
  • Choice of exposure scores for categorical regression in meta-analysis: a case study of a common problem. 
  • Cholestyramine feeding lowers number of colonic apoptotic cells in rat. 
  • Chronic disease management perspectives of colorectal cancer survivors using the Veterans Affairs healthcare system: a qualitative analysis. 
  • Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. 
  • Circulating levels of inflammatory cytokines and risk of colorectal adenomas. 
  • Circulating vitamin D concentration and risk of seven cancers: Mendelian randomisation study. 
  • Cisplatin and 5-fluorouracil infusion for metastatic colorectal carcinoma. Differences in survival in two patient groups with similar response rates. 
  • Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. 
  • Clinical applications of PET in oncology. 
  • Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence. 
  • Clinical, pathologic, and economic parameters of laparoscopic colon resection for cancer. 
  • Clinically relevant changes in family history of cancer over time. 
  • Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance. 
  • Cognitive errors and logistical breakdowns contributing to missed and delayed diagnoses of breast and colorectal cancers: a process analysis of closed malpractice claims. 
  • Colonoscopic indirect lymphangiography in a canine model. 
  • Colonoscopy-based colorectal cancer modeling in mice with CRISPR-Cas9 genome editing and organoid transplantation. 
  • Colorectal Cancer Liver Metastases and Concurrent Extrahepatic Disease Treated With Resection. 
  • Colorectal Cancer Screening Quality Measures: Beyond Colonoscopy. 
  • Colorectal Cancer Statistics From the Veterans Affairs Central Cancer Registry. 
  • Colorectal cancer incidence differs within ethnic Chinese. 
  • Colorectal cancer metastasis determined by carbohydrate-mediated cell adhesion: role of sialyl-LeX antigens. 
  • Colorectal cancer models for novel drug discovery. 
  • Colorectal cancer pelvic recurrences: determinants of resectability. 
  • Colorectal cancer prevention for low-income, sociodemographically-diverse adults in public housing: baseline findings of a randomized controlled trial. 
  • Colorectal cancer risk perceptions and screening intentions in a minority population. 
  • Colorectal cancer screening awareness and intentions among low income, sociodemographically diverse adults under age 50. 
  • Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. 
  • Colorectal cancer screening in asymptomaic adults: comparison of colonoscopy, sigmoidoscopy and fecal occult blood tests. 
  • Colorectal cancer screening in young patients with poor health and severe comorbidity. 
  • Colorectal cancer screening, comorbidity, and follow-up in elderly patients. 
  • Colorectal cancer screening: prevalence among low-income groups with health insurance. 
  • Colorectal cancer surveillance in inflammatory bowel disease: Practice guidelines and recent developments. 
  • Colorectal cancer survivors' needs and preferences for survivorship information. 
  • Colorectal cancer with potentially resectable hepatic metastases: optimizing treatment. 
  • Colorectal cancer. 
  • Colorectal cancer: is the incidence rising in young Iraqi patients? 
  • Colorectal cancer: national and international perspective on the burden of disease and public health impact. 
  • Colorectal cancer: what should patients and families be told to lower the risk of colorectal cancer? 
  • Colorectal ornithine decarboxylase activity in human mucosa and tumors: elevation of enzymatic activity in distal mucosa. 
  • Colorectal polyps: detection with low-dose multi-detector row helical CT colonography versus two sequential colonoscopies. 
  • Colorectal screening patterns and perceptions of risk among African-American users of a community health center. 
  • Colorectal testing utilization and payments in a large cohort of commercially insured US adults. 
  • Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer. 
  • Combined ablation and resection (CARe) as an effective parenchymal sparing treatment for extensive colorectal liver metastases. 
  • Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. 
  • Common familial colorectal cancer linked to chromosome 7q31: a genome-wide analysis. 
  • Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems. 
  • Comparison between perioperative and postoperative chemotherapy after potentially curative hepatic resection for metastatic colorectal cancer. 
  • Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. 
  • Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405. 
  • Comparison of rectal mucosal proliferation measured by proliferating cell nuclear antigen (PCNA) immunohistochemistry and whole crypt dissection. 
  • Comparison of the Dako EGFR pharmDx kit and Zymed EGFR antibody for assessment of EGFR status in colorectal adenocarcinoma. 
  • Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. 
  • Comparison of three physiologically-based pharmacokinetic models for the prediction of contrast agent distribution measured by dynamic MR imaging. 
  • Comprehensive models of human primary and metastatic colorectal tumors in immunodeficient and immunocompetent mice by chemokine targeting. 
  • Computed Tomography Image Texture: A Noninvasive Prognostic Marker of Hepatic Recurrence After Hepatectomy for Metastatic Colorectal Cancer. 
  • Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer. 
  • Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. 
  • Contemporary surgical options for metastatic colorectal cancer. 
  • Contrasting Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening Under Commercial Insurance vs. Medicare. 
  • Conversion to complete resection and/or ablation using hepatic artery infusional chemotherapy in patients with unresectable liver metastases from colorectal cancer: a decade of experience at a single institution. 
  • Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. 
  • Cost-Effectiveness of Colonoscopy-Based Colorectal Cancer Screening in Childhood Cancer Survivors. 
  • County-level cumulative environmental quality associated with cancer incidence. 
  • Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer. 
  • Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. 
  • Cross-species analysis of genetically engineered mouse models of MAPK-driven colorectal cancer identifies hallmarks of the human disease. 
  • Cullin-1 and -2 Protein Expression in Colorectal Cancer: Correlation with Clinicopathological Variables. 
  • Current immunotherapeutic strategies in colon cancer. 
  • Cyclin D1 polymorphism and increased risk of colorectal cancer at young age. 
  • Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. 
  • Cytoablative therapy with combined resection and cryosurgery for limited bilobar hepatic colorectal metastases. 
  • Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal carcinomatosis. 
  • Deciphering Elevated Microsatellite Alterations at Selected Tetra/Pentanucleotide Repeats, Microsatellite Instability, and Loss of Heterozygosity in Colorectal Cancers. 
  • Deficiency of activation-induced cytidine deaminase in a murine model of ulcerative colitis. 
  • Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer. 
  • Defining best supportive care. 
  • Defining payments associated with the treatment of colorectal cancer. 
  • Depression and telomere length in colorectal cancer patients in Saudi Arabia. 
  • Depression in patients with colorectal cancer in Saudi Arabia. 
  • Depressive symptoms and prospective incidence of colorectal cancer in women. 
  • Design of a randomized clinical trial of a colorectal cancer screening decision aid to promote appropriate screening in community-dwelling older adults. 
  • Designing effective vaccines for colorectal cancer. 
  • Detailed pathologic characteristics of the primary colorectal tumor independently predict outcome after hepatectomy for metastases. 
  • Detecting colorectal cancer in stool with the use of multiple genetic targets. 
  • Detection and quantification of mutations in the plasma of patients with colorectal tumors. 
  • Detection of APC mutations in fecal DNA from patients with colorectal tumors. 
  • Detection of Colorectal Hepatic Metastases Is Superior at Standard Radiation Dose CT versus Reduced Dose CT. 
  • Detection of hepatic metastases from colorectal cancer: prospective evaluation of gray scale US versus SonoVue® low mechanical index real time-enhanced US as compared with multidetector-CT or Gd-BOPTA-MRI. 
  • Detection of intestinal dysplasia using angle-resolved low coherence interferometry. 
  • Detection of proximal colorectal cancers through analysis of faecal DNA. 
  • Detection of stool DNA mutations before and after treatment of colorectal neoplasia. 
  • Determinants of medical system delay in the diagnosis of colorectal cancer within the Veteran Affairs Health System. 
  • Developing and sustaining quality improvement partnerships in the VA: the Colorectal Cancer Care Collaborative. 
  • Development and Preliminary Evaluation of a Murine Model of Chronic Radiation-Induced Proctitis. 
  • Development and biological evaluation of ⁹⁹mTc-sulfonamide derivatives for in vivo visualization of CA IX as surrogate tumor hypoxia markers. 
  • Development and initial testing of a computer-based patient decision aid to promote colorectal cancer screening for primary care practice. 
  • Development and quantitative evaluation of a high-resolution metabolomics technology. 
  • Development of a Novel c-MET-Based CTC Detection Platform. 
  • Development of a precision medicine pipeline to identify personalized treatments for colorectal cancer. 
  • Diet and exercise intervention adherence and health-related outcomes among older long-term breast, prostate, and colorectal cancer survivors. 
  • Dietary methionine influences therapy in mouse cancer models and alters human metabolism. 
  • Dietary patterns differ between urban and rural older, long-term survivors of breast, prostate, and colorectal cancer and are associated with body mass index. 
  • Differences between univariate and bivariate models for summarizing diagnostic accuracy may not be large. 
  • Disappearing liver metastases: A systematic review of the current evidence. 
  • Discrete improvement in racial disparity in survival among patients with stage IV colorectal cancer: a 21-year population-based analysis. 
  • Distal margin requirements after preoperative chemoradiotherapy for distal rectal carcinomas: are < or = 1 cm distal margins sufficient? 
  • Double Negativity for Expression of YAP1 and CDX2 Defines an Aggressive Type of Colitis-associated Cancer. 
  • Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. 
  • Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer. 
  • Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. 
  • Dynamic contrast-enhanced MR microscopy identifies regions of therapeutic response in a preclinical model of colorectal adenocarcinoma. 
  • ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. 
  • Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study. 
  • Ectopic expression of mucins in colorectal cancer metastasis. 
  • Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. 
  • Effect of Radiation Dose Reduction and Reconstruction Algorithm on Image Noise, Contrast, Resolution, and Detectability of Subtle Hypoattenuating Liver Lesions at Multidetector CT: Filtered Back Projection versus a Commercial Model-based Iterative Reconstruction Algorithm. 
  • Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. 
  • Effects of communicating social comparison information on risk perceptions for colorectal cancer. 
  • Effects of home-based diet and exercise on functional outcomes among older, overweight long-term cancer survivors: RENEW: a randomized controlled trial. 
  • Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. 
  • Efficiency of colorectal cancer care among veterans: analysis of treatment wait times at Veterans Affairs Medical Centers. 
  • Enrollment of patients with lung and colorectal cancers onto clinical trials. 
  • Epigenetic Heterogeneity in Human Colorectal Tumors Reveals Preferential Conservation And Evidence of Immune Surveillance. 
  • Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis. 
  • Epithelial Smad4 Deletion Up-Regulates Inflammation and Promotes Inflammation-Associated Cancer. 
  • Ets-1 and runx2 regulate transcription of a metastatic gene, osteopontin, in murine colorectal cancer cells. 
  • Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. 
  • Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma. 
  • Evaluation of hypertension as a marker of bevacizumab efficacy. 
  • Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer. 
  • Evaluation of the effect of transcytolemmal water exchange analysis for therapeutic response assessment using DCE-MRI: a comparison study. 
  • Everolimus in colorectal cancer. 
  • Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases. 
  • Examining potential colorectal cancer care disparities in the Veterans Affairs health care system. 
  • Expression of platelet-derived endothelial cell growth factor correlates with good prognosis in patients with colorectal carcinoma. 
  • Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer. 
  • Factors affecting the communication experiences of newly diagnosed colorectal cancer patients. 
  • Fellowship Colonoscopy Training and Preparedness for Independent Gastroenterology Practice. 
  • Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab. 
  • Folate receptor-α expression in resectable hepatic colorectal cancer metastases: patterns and significance. 
  • Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer. 
  • Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. 
  • Functional status declines among cancer survivors: trajectory and contributing factors. 
  • GSTM1, GSTT1, GSTP1, GSTA1 and colorectal cancer risk: a comprehensive meta-analysis. 
  • Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). 
  • Gene expression profiles accurately predict outcome following liver resection in patients with metastatic colorectal cancer. 
  • General performance on a numeracy scale among highly educated samples. 
  • Genetic And Morphological Evaluation (GAME) score for patients with colorectal liver metastases. 
  • Genetic editing of colonic organoids provides a molecularly distinct and orthotopic preclinical model of serrated carcinogenesis. 
  • Genetic instability of microsatellites in endometrial carcinoma. 
  • Genetic variation determines VEGF-A plasma levels in cancer patients. 
  • Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. 
  • Genomic distribution of CHD7 on chromatin tracks H3K4 methylation patterns. 
  • Genomically informed small-molecule drugs overcome resistance to a sustained-release formulation of an engineered death receptor agonist in patient-derived tumor models. 
  • Gentamicin sponge for infection prophylaxis in colorectal surgery. 
  • Gentamicin-collagen sponge for infection prophylaxis in colorectal surgery. 
  • Group trajectory analysis helps to identify older cancer survivors who benefit from distance-based lifestyle interventions. 
  • HER2 testing in metastatic colorectal cancer: ready for prime time? 
  • Health-protective and adverse effects of the apolipoprotein E epsilon2 allele in older men. 
  • Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. 
  • Helicobacter pylori Biomarkers and Risk of Colorectal Oncogenesis--Response. 
  • Helicobacter pylori and colorectal cancer-A bacterium going abroad? 
  • Helicobacter pylori protein-specific antibodies and risk of colorectal cancer. 
  • Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. 
  • Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). 
  • Hepatic artery infusional chemotherapy in patients with unresectable colorectal liver metastases and extrahepatic disease. 
  • Hepatic pedicle clamping during hepatic resection for colorectal liver metastases: no impact on survival or hepatic recurrence. 
  • Hereditary brain tumor with a homozygous germline mutation in PMS2: pedigree analysis and prenatal screening in a family with constitutional mismatch repair deficiency (CMMRD) syndrome. 
  • Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. 
  • Hidden biases in an observational study of bevacizumab beyond progression. 
  • High frequency of mutations of the PIK3CA gene in human cancers. 
  • High success rate of repeat colonoscopy with standard endoscopes in patients referred for prior incomplete colonoscopy. 
  • High-Risk Adenomas at Screening Colonoscopy Remain Predictive of Future High-Risk Adenomas Despite an Intervening Negative Colonoscopy. 
  • High-depth sequencing of over 750 genes supports linear progression of primary tumors and metastases in most patients with liver-limited metastatic colorectal cancer. 
  • High-resolution mapping of heteroduplex DNA formed during UV-induced and spontaneous mitotic recombination events in yeast. 
  • Histological and molecular evaluation of patient-derived colorectal cancer explants. 
  • Histopathological growth patterns as biomarker for adjuvant systemic chemotherapy in patients with resected colorectal liver metastases. 
  • Histopathological prognostic factors influencing long-term prognosis after surgical resection for hepatic metastases from colorectal cancer. 
  • Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. 
  • Hospital readmissions after liver surgery for metastatic colorectal cancer. 
  • How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated-choice survey. 
  • Human colonic sulfomucin identified by a specific monoclonal antibody. 
  • Human smooth muscle alpha-actin gene is a transcriptional target of the p53 tumor suppressor protein. 
  • Hypercholesterolemia Increases Colorectal Cancer Incidence by Reducing Production of NKT and γδ T Cells from Hematopoietic Stem Cells. 
  • ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. 
  • Identification of DK419, a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth. 
  • Immunogenicity and Optimal Timing of 13-Valent Pneumococcal Conjugate Vaccination during Adjuvant Chemotherapy in Gastric and Colorectal Cancer: A Randomized Controlled Trial. 
  • Immunohistochemical analysis of statin in colorectal adenocarcinoma, polyps, and normal mucosa. 
  • Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). 
  • Impact of Disgust on Intentions to Undergo Colorectal Surgery. 
  • Impact of colorectal cancer diagnosis and treatment on health-related quality of life among older Americans: a population-based, case-control study. 
  • Impact of patient navigation on timely cancer care: the Patient Navigation Research Program. 
  • Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. 
  • Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. 
  • Impact of simultaneous diaphragm resection during hepatectomy for treatment of metastatic colorectal cancer. 
  • Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. 
  • Implementation of a Hepatic Artery Infusion Program: Initial Patient Selection and Perioperative Outcomes of Concurrent Hepatic Artery Infusion and Systemic Chemotherapy for Colorectal Liver Metastases. 
  • Importance of quality-of-life priorities and preferences surrounding treatment decision making in patients with cancer and oncology clinicians. 
  • Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. 
  • Improving colorectal cancer screening and care in the Veterans Affairs Healthcare system. 
  • Improving the clinical risk score: an analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases. 
  • In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis. 
  • Inconsistencies in Colonic Tattooing Practice: Differences in Reported and Actual Practices at a Tertiary Medical Center. 
  • Increase in circulating levels of IGF-1 and IGF-1/IGFBP-3 molar ratio over a decade is associated with colorectal adenomatous polyps. 
  • Increased HMGB1 and cleaved caspase-3 stimulate the proliferation of tumor cells and are correlated with the poor prognosis in colorectal cancer. 
  • Increased content of an endogenous lactose-binding lectin in human colorectal carcinoma progressed to metastatic stages. 
  • Increased expression of sialyl-dimeric LeX antigen in liver metastases of human colorectal carcinoma. 
  • Increased rectal microbial richness is associated with the presence of colorectal adenomas in humans. 
  • Increasing colorectal cancer screening among individuals in the carpentry trade: test of risk communication interventions. 
  • Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. 
  • Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery. 
  • Influence of ATM function on telomere metabolism. 
  • Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. 
  • Interaction of Galpha 12 and Galpha 13 with the cytoplasmic domain of cadherin provides a mechanism for beta -catenin release. 
  • Interinstitutional variation in management decisions for treatment of 4 common types of cancer: A multi-institutional cohort study. 
  • Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. 
  • Intrahepatic mitomycin C as a salvage treatment for patients with hepatic metastases from colorectal carcinoma. 
  • Intraoperative pelvic brachytherapy for treatment of locally advanced or recurrent colorectal cancer. 
  • Intraportal injection of monoclonal antibody in nude mice bearing hepatic metastases. 
  • Irinotecan: promising activity in the treatment of malignant glioma. 
  • Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-institutional Analysis of 1497 Patients. 
  • Is colorectal cancer surveillance cost-effective in patients with ulcerative colitis? 
  • Is obesity an advantage in patients with colorectal cancer? 
  • Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? A review of the literature previously presented: poster at the 2008 Gastrointestinal Cancer Symposium (Abstract No. 512). 
  • Is there a role for simultaneous hepatic and colorectal resections? A contemporary view from NSQIP. 
  • Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor cells. 
  • KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer. 
  • KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. 
  • KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. 
  • LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers. 
  • Lactose-binding lectin expression in human colorectal carcinomas. Relation to tumor progression. 
  • Laparoscopic colon resection for cancer--a favorable view. 
  • Laparoscopic resection for colon cancer: a favorable view. 
  • Laparoscopic staging for hepatobiliary carcinoma. 
  • Laparoscopic synchronous resection of colorectal cancer and liver metastases: A systematic review. 
  • Laparoscopic versus open resection of colorectal liver metastasis. 
  • Left hepatic trisectionectomy for hepatobiliary malignancy: results and an appraisal of its current role. 
  • Less is more: salvageability as the new creed in surgery of colorectal liver metastatic disease. 
  • Liver transplantation for unresectable colorectal liver metastases: A systematic review. 
  • Living with long-term consequences: Experience of follow-up care and support needs among Asian long-term colorectal cancer survivors. 
  • Long-term oncologic outcomes for simultaneous resection of synchronous metastatic liver and primary colorectal cancer. 
  • Long-term outcomes following microwave ablation for liver malignancies. 
  • Long-term outcomes following tumor ablation for treatment of bilateral colorectal liver metastases. 
  • Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report. 
  • Longitudinal adherence to fecal occult blood testing impacts colorectal cancer screening quality. 
  • Longitudinal associations between BMI change and the risks of colorectal cancer incidence, cancer-relate and all-cause mortality among 81,388 older adults : BMI change and the risks of colorectal cancer incidence and mortality. 
  • Loss of PTPRM associates with the pathogenic development of colorectal adenoma-carcinoma sequence. 
  • Low-cost, scalable laser scanning module for real-time reflectance and fluorescence confocal microscopy. 
  • Lymph node metastases develop through a wider evolutionary bottleneck than distant metastases. 
  • Lymphatic mapping and sentinel node identification for colorectal cancer. 
  • MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. 
  • MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. 
  • Magnetic resonance histology. 
  • Maintenance therapy for first-line metastatic colorectal cancer: activity and sustainability. 
  • Manipulating perceptions of colorectal cancer threat: implications for screening intentions and behaviors. 
  • Measuring patient preferences for colorectal cancer screening using a choice-format survey. 
  • Mediating effects of cancer risk factors on the association between race and cancer incidence: analysis of the NIH-AARP Diet and Health Study. 
  • Mendelian randomization study of adiposity-related traits and risk of breast, ovarian, prostate, lung and colorectal cancer. 
  • Mental health outcomes during colorectal cancer survivorship: a review of the literature. 
  • Message Framing and Physical Activity Promotion in Colorectal Cancer Survivors. 
  • Meta-analyses of colorectal cancer risk factors. 
  • Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. 
  • Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancer-Response. 
  • Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancer. 
  • Methodological remarks concerning the recent meta-analysis on p53 codon 72 polymorphism and colorectal cancer risk. 
  • Methodological remarks on the recent meta-analysis examining the association between glutathione-S-transferase M1 polymorphism and sporadic colorectal cancer risk. 
  • Micropapillary colorectal carcinoma: clinical, pathological and molecular properties, including evidence of epithelial-mesenchymal transition. 
  • Microsatellite Instability Is Common in Colorectal Cancer in Native Nigerians. 
  • Midlife Cardiorespiratory Fitness, Incident Cancer, and Survival After Cancer in Men: The Cooper Center Longitudinal Study. 
  • Minimal barriers to invasion during human colorectal tumor growth. 
  • Minimally invasive liver resection for metastatic colorectal cancer: a multi-institutional, international report of safety, feasibility, and early outcomes. 
  • Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients. 
  • Modeling qRT-PCR dynamics with application to cancer biomarker quantification. 
  • Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy. 
  • Modified V-Y Fasciocutaneous Flap Reconstruction After Abdominoperineal Resection in Irradiated Patients Prevents Wound Dehiscence and Associated Complications: A Retrospective Analysis and Benchtop Confirmation. 
  • Modifying attributions of colorectal cancer risk. 
  • Molecular approaches for colorectal cancer screening. 
  • Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomas. 
  • Molecular profile and copy number analysis of sporadic colorectal cancer in Taiwan. 
  • Molecular testing in colorectal cancer: diagnosis of Lynch syndrome and personalized cancer medicine. 
  • Monoclonal antibodies: the foundation of therapy for colorectal cancer in the 21st century? 
  • Monoclonal antibody against human colonic sulfomucin: immunochemical detection of its binding sites in colonic mucosa, colorectal primary carcinoma, and metastases. 
  • Mortality Trends in Colorectal Cancer in China During 2000-2015: A Joinpoint Regression and Age-Period-Cohort Analysis. 
  • Mortality and follow-up colonoscopy after colorectal cancer. 
  • Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. 
  • Muir-Torre syndrome. 
  • Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study. 
  • Multicolor in vitro translation. 
  • Multiregion ultra-deep sequencing reveals early intermixing and variable levels of intratumoral heterogeneity in colorectal cancer. 
  • Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803. 
  • Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases. 
  • Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. 
  • Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center. 
  • Mutational analysis of the tyrosine phosphatome in colorectal cancers. 
  • NAFLD and extrahepatic cancers: have a look at the colon. 
  • NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. 
  • Narratives that address affective forecasting errors reduce perceived barriers to colorectal cancer screening. 
  • National Trends in End-of-Life Care for Veterans With Advanced Cancer in the Veterans Health Administration: 2009 to 2016. 
  • Natural history of patients with subcentimeter pulmonary nodules undergoing hepatic resection for metastatic colorectal cancer. 
  • New combinations in metastatic colorectal cancer: what are our expectations? 
  • Niclosamide-induced Wnt signaling inhibition in colorectal cancer is mediated by autophagy. 
  • Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. 
  • Non-alcoholic fatty liver diseases and risk of colorectal neoplasia. 
  • Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. 
  • Obesity-Induced Colorectal Cancer Is Driven by Caloric Silencing of the Guanylin-GUCY2C Paracrine Signaling Axis. 
  • Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer. 
  • Operative Results and Oncologic Outcomes of Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) Versus Two-Stage Hepatectomy (TSH) in Patients with Unresectable Colorectal Liver Metastases: A Systematic Review and Meta-Analysis. 
  • Operative morbidity and survival following hepatectomy for colorectal liver metastasis in octogenarians: a contemporary case matched series. 
  • Outcomes, preferences for resuscitation, and physician-patient communication among patients with metastatic colorectal cancer. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. 
  • Overall survival or other clinical benefits from adjuvant selective intraarterial chemotherapy in patients undergoing curative liver resection for metastatic colorectal tumor. 
  • Overview of genetically engineered mouse models of colorectal carcinoma to enable translational biology and drug development. 
  • PET concerns in bevacizumab treatment. 
  • POT1 mutation spectrum in tumour types commonly diagnosed among POT1-associated hereditary cancer syndrome families. 
  • Palliative treatment of metastatic colorectal cancer: what is the optimal approach? 
  • Palliative treatment of rectal cancer: is radiotherapy alone a good option? 
  • Parenchymal-Sparing Versus Anatomic Liver Resection for Colorectal Liver Metastases: a Systematic Review. 
  • Parenchymal-sparing Hepatectomy as the New Doctrine in the Treatment of Liver-metastatic Colorectal Disease: Beyond Oncological Outcomes. 
  • Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome. 
  • Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. 
  • Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors. 
  • Patient Triage for Resection of Metastatic Colorectal Cancer to the Liver: Can We Do Better Using MRI? 
  • Patient and primary care provider experience using a family health history collection, risk stratification, and clinical decision support tool: a type 2 hybrid controlled implementation-effectiveness trial. 
  • Patient characteristics associated with the level of patient-reported care coordination among male patients with colorectal cancer in the Veterans Affairs health care system. 
  • Patient-reported quality of supportive care among patients with colorectal cancer in the Veterans Affairs Health Care System. 
  • Patterns of recurrence after ablation of colorectal cancer liver metastases. 
  • Patterns of recurrence of colorectal cancer. 
  • Pelvic exenteration for the treatment of locally advanced colorectal and bladder malignancies in the modern era. 
  • Perioperative Hepatic Arterial Infusion Pump Chemotherapy Is Associated With Longer Survival After Resection of Colorectal Liver Metastases: A Propensity Score Analysis. 
  • Perioperative and oncologic outcomes of minimally invasive liver resection for colorectal metastases: A case-control study of 130 patients. 
  • Perioperative complications influence recurrence and survival after resection of hepatic colorectal metastases. 
  • Peripheral Circulating Tumor DNA Detection Predicts Poor Outcomes After Liver Resection for Metastatic Colorectal Cancer. 
  • Personalisation of colorectal cancer screening. 
  • Personalized treatment in patients with colorectal liver metastases. 
  • Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. 
  • Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes. 
  • Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer. 
  • Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy. 
  • Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. 
  • Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. 
  • Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. 
  • Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. 
  • Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer. 
  • Phase I trial of semustine plus weekly fluorouracil and high-dose leucovorin calcium in patients with advanced colorectal cancer. 
  • Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. 
  • Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM). 
  • Phase II study of MGI-114 administered intravenously for 5 days every 28 days to patients with metastatic colorectal cancer. 
  • Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. 
  • Phase II study of didemnin B in advanced colorectal cancer. 
  • Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer. 
  • Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma. 
  • Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. 
  • Phase II study of gemcitabine in advanced colorectal adenocarcinoma. 
  • Phase II study of intravenous CI-958 in metastatic colorectal adenocarcinoma. 
  • Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. 
  • Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. 
  • Phase II trial of 5-fluorouracil, folinic acid and recombinant alpha-2a-interferon in patients with advanced colorectal cancer. 
  • Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinoma. 
  • Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma. 
  • Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a Southwest Oncology Group study. 
  • Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma. 
  • Phase II trial of fazarabine in advanced colorectal carcinoma. 
  • Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. 
  • Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. 
  • Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity. 
  • Phase II trial of intravenous melphalan in advanced colorectal carcinoma. 
  • Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma. 
  • Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. 
  • Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). 
  • Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. 
  • Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. 
  • Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. 
  • Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. 
  • Pilot feasibility study of a telephone-based couples intervention for physical intimacy and sexual concerns in colorectal cancer. 
  • Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). 
  • Population-based assessment of cancer survivors' financial burden and quality of life: a prospective cohort study. 
  • Positive postoperative CEA is a strong predictor of recurrence for patients after resection for colorectal liver metastases. 
  • Precision Medicine for CRC Patients in the Veteran Population: State-of-the-Art, Challenges and Research Directions. 
  • Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in Chemoradiotherapy. 
  • Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope. 
  • Predicting Colorectal Cancer Screening among Adults Who Have Never Been Screened: Testing the Interaction between Message Framing and Tailored Risk Feedback. 
  • Prediction of Recurrence Patterns from Hepatic Parenchymal Disease After Resection of Colorectal Liver Metastases. 
  • Predictors of adverse smoking outcomes in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. 
  • Predictors of colorectal cancer surveillance among survivors of childhood cancer treated with radiation: a report from the Childhood Cancer Survivor Study. 
  • Preincisional intravenous pentoxifylline attenuating perioperative cytokine response, reducing morphine consumption, and improving recovery of bowel function in patients undergoing colorectal cancer surgery. 
  • Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. 
  • Priceless GEMMs: genetically engineered mouse models for colorectal cancer drug development. 
  • Primary care providers' needs and preferences for information about colorectal cancer survivorship care. 
  • Primary lesion location influences postoperative survival in patients with metastatic colorectal spinal lesions. 
  • Primary tumor location as a prognostic factor in metastatic colorectal cancer. 
  • Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial. 
  • Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. 
  • Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. 
  • Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. 
  • Prognostic significance of early recurrence: a conditional survival analysis in patients with resected colorectal liver metastasis. 
  • Prognostic significance of primary tumor sidedness in patients undergoing liver resection for metastatic colorectal cancer. 
  • Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. 
  • Prognostic variables in patients with hepatic metastases from colorectal cancer. Importance of medical assessment of liver involvement. 
  • Proliferative activity at colonic anastomoses as determined by statin. A nonproliferation-specific nuclear protein. 
  • Proliferative activity of colonic mucosa at different distances from primary adenocarcinoma as determined by the presence of statin: a nonproliferation-specific nuclear protein. 
  • Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases. 
  • Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential. 
  • Psychometric validation and reliability analysis of a Spanish version of the patient satisfaction with cancer-related care measure: a patient navigation research program study. 
  • Quality measures for the use of adjuvant chemotherapy and radiation therapy in patients with colorectal cancer: a systematic review. 
  • Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial. 
  • Quality of nonmetastatic colorectal cancer care in the Department of Veterans Affairs. 
  • Quantitative imaging features of pretreatment CT predict volumetric response to chemotherapy in patients with colorectal liver metastases. 
  • Quantitative proteome analysis of colorectal cancer-related differential proteins. 
  • RNA-binding protein HuR enhances p53 translation in response to ultraviolet light irradiation. 
  • Race, treatment, and survival among colorectal carcinoma patients in an equal-access medical system. 
  • Race/ethnicity and socio-economic differences in colorectal cancer surgery outcomes: analysis of the nationwide inpatient sample. 
  • Racial/ethnic disparities in de novo metastases sites and survival outcomes for patients with primary breast, colorectal, and prostate cancer. 
  • Radio-induced modulation of transforming growth factor beta1 sensitivity in a p53 wild-type human colorectal-cancer cell line. 
  • Radiomics-based prediction of microsatellite instability in colorectal cancer at initial computed tomography evaluation. 
  • Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. 
  • Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. 
  • Randomized phase III study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-lomustine for patients with advanced colorectal cancer. 
  • Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer. 
  • RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer. 
  • Re: Mortality and follow-up colonoscopy after colorectal cancer. 
  • Reach out to ENhancE Wellness in Older Cancer Survivors (RENEW): design, methods and recruitment challenges of a home-based exercise and diet intervention to improve physical function among long-term survivors of breast, prostate, and colorectal cancer. 
  • Reactions to online colorectal cancer risk estimates among a nationally representative sample of adults who have never been screened. 
  • Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. 
  • Rectal mucosal ornithine decarboxylase activity is not a useful marker of risk for colorectal neoplasia. 
  • Rectovaginal examinations and human papillomavirus: can we decrease the risk of colorectal infection? 
  • Recurrence After Partial Hepatectomy for Metastatic Colorectal Cancer: Potentially Curative Role of Salvage Repeat Resection. 
  • Recurrence patterns following irreversible electroporation for hepatic malignancies. 
  • Recurrent tumor after resection of hepatic metastases from colorectal carcinoma: location and time of discovery as determined by CT. 
  • Reduced ATR or Chk1 expression leads to chromosome instability and chemosensitization of mismatch repair-deficient colorectal cancer cells. 
  • Reduced expression of mismatch repair genes in colorectal cancer patients in Egypt. 
  • Regenerative Reprogramming of the Intestinal Stem Cell State via Hippo Signaling Suppresses Metastatic Colorectal Cancer. 
  • Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme? 
  • Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. 
  • Relationship between sleep and exercise as colorectal cancer survivors transition off treatment. 
  • Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. 
  • Relationship of epithelial ovarian cancer to other malignancies within families. 
  • Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer. 
  • Relative quantification based on logistic models for individual polymerase chain reactions. 
  • Religiosity and Telomere Length in Colorectal Cancer Patients in Saudi Arabia. 
  • Religious beliefs, practices, and health in colorectal cancer patients in Saudi Arabia. 
  • Reply to S. Sorscher. 
  • Representativeness of participants in the cancer care outcomes research and surveillance consortium relative to the surveillance, epidemiology, and end results program. 
  • Reproducibility and variability of the rectal mucosal proliferation index using proliferating cell nuclear antigen immunohistochemistry. 
  • Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate? 
  • Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR. 
  • Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. 
  • Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases. 
  • Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. 
  • Restoration of mismatch repair to nuclear extracts of H6 colorectal tumor cells by a heterodimer of human MutL homologs. 
  • Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma. 
  • Risk Factors for Early-Onset Colorectal Cancer. 
  • Risk of occult irresectable disease at liver resection for hepatic colorectal cancer metastases: a contemporary analysis. 
  • Role of mast cells in inflammatory bowel disease and inflammation-associated colorectal neoplasia in IL-10-deficient mice. 
  • Rural-urban differences in health behaviors and outcomes among older, overweight, long-term cancer survivors in the RENEW randomized control trial. 
  • SATB2 protein expression by immunohistochemistry is a sensitive and specific marker of appendiceal and rectosigmoid well differentiated neuroendocrine tumours. 
  • Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study. 
  • Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer. 
  • Screening and surveillance for second malignant neoplasms in adult survivors of childhood cancer: a report from the childhood cancer survivor study. 
  • Screening for colorectal cancer. A comparison of 3 fecal occult blood tests. 
  • Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study. 
  • Self-affirmation moderates effects of unrealistic optimism and pessimism on reactions to tailored risk feedback. 
  • Sensitive digital quantification of DNA methylation in clinical samples. 
  • Serologic Response to Helicobacter pylori Proteins Associated With Risk of Colorectal Cancer Among Diverse Populations in the United States. 
  • Shared heritability and functional enrichment across six solid cancers. 
  • Short-Term Risk of Performing Concurrent Procedures with Hepatic Artery Infusion Pump Placement. 
  • Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. 
  • Single-Cell Transcriptomics Reveals Heterogeneity and Drug Response of Human Colorectal Cancer Organoids. 
  • Single-Center Experience with Magnetic Retraction in Colorectal Surgery. 
  • Sleep quality in individuals diagnosed with colorectal cancer: Factors associated with sleep disturbance as patients transition off treatment. 
  • Smoking Status and Survival Among a National Cohort of Lung and Colorectal Cancer Patients. 
  • Solid tumor second primary neoplasms: who is at risk, what can we do? 
  • Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. 
  • Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. 
  • Spatial mutation patterns as markers of early colorectal tumor cell mobility. 
  • Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. 
  • Staging of colorectal cancer: past, present, and future. 
  • Stigma, perceived blame, self-blame, and depressive symptoms in men with colorectal cancer. 
  • Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer. 
  • Structured Approach for Evaluating Strategies for Cancer Ascertainment Using Large-Scale Electronic Health Record Data. 
  • Summaries for patients. Increased risk for gastrointestinal cancer in childhood cancer survivors. 
  • Surgery for colorectal cancer in elderly patients: a systematic review. Colorectal Cancer Collaborative Group. 
  • Surgical Resection of the Primary Tumor in Stage IV Colorectal Cancer Without Metastasectomy is Associated With Improved Overall Survival Compared With Chemotherapy/Radiation Therapy Alone. 
  • Surgical management of pulmonary metastases. 
  • Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. 
  • Surveillance issues in inflammatory bowel disease: ulcerative colitis. 
  • Survivorship care planning and its influence on long-term patient-reported outcomes among colorectal and lung cancer survivors: the CanCORS disease-free survivor follow-up study. 
  • Symptoms, weight loss, and physical function in a lifestyle intervention study of older cancer survivors. 
  • Synchronous colorectal liver metastases: is it time to reconsider traditional paradigms of management? 
  • Synchronous colorectal liver metastases: the "surgeon as oncologist" perspective. 
  • Synchronous resection of esophageal cancer and other organ malignancies: A systematic review. 
  • Synergistic cytotoxicity with 2'-deoxy-5-azacytidine and topotecan in vitro and in vivo. 
  • Synthesis and biological evaluation of a 99mTc-labelled sulfonamide conjugate for in vivo visualization of carbonic anhydrase IX expression in tumor hypoxia. 
  • Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. 
  • Systemic markers of oxidative status and colorectal adenomatous polyps. 
  • T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers. 
  • Talking with patients about dying. 
  • Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. 
  • Targeted therapy of colorectal cancer: clinical experience with bevacizumab. 
  • Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. 
  • Targeting CXCR4-dependent immunosuppressive Ly6C^low monocytes improves antiangiogenic therapy in colorectal cancer. 
  • Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. 
  • Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. 
  • Tea consumption, apoptosis, and colorectal adenomas. 
  • Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. 
  • Technology evaluation: CEA-TRICOM, Therion Biologics Corp. 
  • Technology evaluation: Rexin-G, Epeius Biotechnologies. 
  • Testing different formats for communicating colorectal cancer risk. 
  • The Caspase-3/PKCδ/Akt/VEGF-A Signaling Pathway Mediates Tumor Repopulation during Radiotherapy. 
  • The Chicago Consensus on Peritoneal Surface Malignancies: Management of Colorectal Metastases. 
  • The Chicago Consensus on peritoneal surface malignancies: Management of colorectal metastases. 
  • The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. 
  • The Effect of Frailty Index on Early Outcomes after Combined Colorectal and Liver Resections. 
  • The Feasibility and Acceptability of a Cognitive Behavioral Therapy-Based Intervention for Patients With Advanced Colorectal Cancer. 
  • The accuracy and completeness for receipt of colorectal cancer care using Veterans Health Administration administrative data. 
  • The activity of RhoA is correlated with lymph node metastasis in human colorectal cancer. 
  • The anatomical distribution of colorectal polyps at colonoscopy. 
  • The apolipoprotein E epsilon2 allele and aging-associated health deterioration in older males. 
  • The approach to the patient with single and multiple liver metastases, pulmonary metastases, and intra-abdominal metastases from colorectal carcinoma. 
  • The appropriateness of 30-day mortality as a quality metric in colorectal cancer surgery. 
  • The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. 
  • The colorectal microRNAome. 
  • The diagnostic accuracy/efficacy of MRI in differentiating hepatic hemangiomas from metastatic colorectal/breast carcinoma: a multiple reader ROC analysis using a jackknife technique. 
  • The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. 
  • The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. 
  • The effect of comorbid illness on receipt of cancer screening by older people. 
  • The effects of cancer and racial disparities in health-related quality of life among older Americans: a case-control, population-based study. 
  • The efficacy of tailored print materials in promoting colorectal cancer screening: results from a randomized trial involving callers to the National Cancer Institute's Cancer Information Service. 
  • The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. 
  • The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer. 
  • The role of F-18 FDG positron emission tomography in preoperative assessment of the liver in patients being considered for curative resection of hepatic metastases from colorectal cancer. 
  • The role of glutathione S-transferase P1-1 in colorectal cancer: friend or foe? 
  • The role of hPMS1 and hPMS2 in predisposing to colorectal cancer. 
  • The role of targeted therapy in the treatment of colorectal cancer. 
  • The sentinel node in colorectal carcinoma. Mapping technique, pathologic assessment, and clinical relevance. 
  • The treatment of colorectal carcinoma: standard chemotherapy and beyond. 
  • The value of calprotectin S100A8/A9 complex as a biomarker in colorectal cancer: A systematic review. 
  • Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. 
  • Thirty years of rectal cancer research: a brief history. 
  • Time is money for both the healthy and the sick. 
  • Time-to-Surgery and Survival Outcomes in Resectable Colorectal Liver Metastases: A Multi-Institutional Evaluation. 
  • Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multi-institutional analysis. 
  • Trajectory of overall health from self-report and factors contributing to health declines among cancer survivors. 
  • Transportation as a barrier to colorectal cancer care. 
  • Transportation: a vehicle or roadblock to cancer care for VA patients with colorectal cancer? 
  • Treatment of advanced colorectal cancer. 
  • Treatment of extensive metastatic colorectal cancer to the liver with systemic and hepatic arterial infusion chemotherapy and two-stage hepatic resection: the role of salvage therapy for recurrent disease. 
  • Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. 
  • Treatment-related toxicity and supportive care in metastatic colorectal cancer. 
  • Trends in up-to-date status in colorectal cancer screening, North Carolina, 1998-2002. 
  • Tumor MHC class I expression improves the prognostic value of T-cell density in resected colorectal liver metastases. 
  • Tumor-Associated Macrophage Infiltration in Colorectal Cancer Liver Metastases is Associated With Better Outcome. 
  • Ubiquitination of the DNA-damage checkpoint kinase CHK1 by TRAF4 is required for CHK1 activation. 
  • Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective. 
  • Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy. 
  • Updates in colorectal cancer screening in inflammatory bowel disease. 
  • Urinary isothiocyanates; glutathione S-transferase M1, T1, and P1 polymorphisms; and risk of colorectal cancer: the Multiethnic Cohort Study. 
  • Use of NCCN Guidelines, Other Guidelines, and Biomarkers for Colorectal Cancer Screening. 
  • Use of intraoperative ablation as an adjunct to surgical resection in the treatment of recurrent colorectal liver metastases. 
  • Use of nonsteroidal antiinflammatory drugs and distal large bowel cancer in whites and African Americans. 
  • Use of pathway information in molecular epidemiology. 
  • Use of psychosocial support services among male Veterans Affairs colorectal cancer patients. 
  • Use of vitamins, minerals, and nutritional supplements by participants in a chemoprevention trial. 
  • Using NCCN clinical practice guidelines in oncology to measure the quality of colorectal cancer care in the veterans health administration. 
  • Using ordinal logistic regression to estimate the likelihood of colorectal neoplasia. 
  • Utility of Image Guidance in the Localization of Disappearing Colorectal Liver Metastases. 
  • Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. 
  • Utilization of hospital-based chaplain services among newly diagnosed male Veterans Affairs colorectal cancer patients. 
  • Validation of a questionnaire to assess self-reported colorectal cancer screening status using face-to-face administration. 
  • Valuations of genetic test information for treatable conditions: the case of colorectal cancer screening. 
  • Variability in resource use: diagnosing colorectal cancer. 
  • Variation in the cost of medications for the treatment of colorectal cancer. 
  • Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. 
  • Virtual colonoscopy. 
  • Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. 
  • What's new in general surgery: surgical oncology. 
  • Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management. 
  • Why information alone is not enough: behavioral economics and the future of genomic medicine. 
  • With Colorectal Cancer Treatment, Physical Toxicity Is Not the Only Concern. 
  • Wnt addiction of genetically defined cancers reversed by PORCN inhibition. 
  • Ziv-aflibercept: binding to more than VEGF-A--does more matter? 
  • ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. 
  • mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. 
  • miR-1269 promotes metastasis and forms a positive feedback loop with TGF-β. 
  • p38 MAPK in development and cancer. 
  • p53 inhibits alpha 6 beta 4 integrin survival signaling by promoting the caspase 3-dependent cleavage of AKT/PKB. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Gellad, Ziad F., Associate Professor of Medicine, Medicine, Gastroenterology
  • Grambow, Steven C., Assistant Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Hyslop, Terry, Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • McCall, Shannon Jones, Associate Professor of Pathology, Pathology
  • Moorman, Patricia Gripka, Professor Emeritus in Family Medicine and Community Health, Duke Cancer Institute
  • Olsen, Maren Karine, Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Palmer, Gregory M., Associate Professor of Radiation Oncology, Radiation Oncology
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Turkington, Timothy Garvey, Associate Professor in Radiology, Radiology
  • Uronis, Hope Elizabeth, Associate Professor of Medicine, Medicine, Medical Oncology
  • Yan, Hai, Henry S. Friedman Distinguished Professor of Neuro-Oncology in the School of Medicine, Pathology
  • Yancy Jr., William Samuel, Associate Professor of Medicine, Medicine, General Internal Medicine
  • Zafar, Syed Yousuf, Associate Professor of Medicine, Duke Science & Society